Implicity Introduces a Remote Monitoring Solution for Heart Failure Patients

Implicity Introduces a Remote Monitoring Solution for Heart Failure Patients

Bayer HealthCare SAS France signs a commercial agreement with the company to accelerate global adoption and improve the quality of care for heart failure patients worldwide.

FREMONT, CA: Implicity, a leader in remote patient monitoring software and cardiac data management systems, has announced a new dedicated heart failure solution to its product and service offerings. Withings, a significant provider of linked devices for remote patient monitoring, collaborated on the new AI-based tool.

Implicity's universal platform now supports data collected by devices in the Withings ecosystem, including smart scales, in addition to integrating all types of cardiac implanted electronic devices (CIEDs).In addition, Implicity's heart failure solution instantly warns medical care teams when a patient gets remotely monitored for heart failure is missing or inconsistent weight data or has unexpected weight gain, thanks to a CE-marked medical-grade algorithm.

More than a dozen medical centres in France are already using Implicity's heart failure treatment. In addition, the company recently announced a commercial partnership with Bayer HealthCare SAS France to help boost its adoption.

"Implicity and Bayer have a shared mission to not only improve the quality of life for patients with heart failure, but also optimize their care and help reduce overall healthcare costs," said Dr Rosier. "Drawing on Bayer's strong network of medical professionals and its recognized expertise in cardiology, we can speed up the international roll-out of this unique solution – providing healthcare professionals around the globe with a more holistic approach to the management of heart diseases."

"Comprehensive management includes treatment, prevention and prediction. Implicity's solution is part of this approach. This a very promising medical technology company with concrete research and development projects and solid data and AI expertise. We are delighted with this collaboration and to be able to contribute together to accelerate the adoption of heart failure telemonitoring in France," said Guilhem Maffre-Bauge, Director of Business Unit General practice, Bayer Pharmaceuticals France.

Heart failure is still the most significant cause of death worldwide, impacting around 5.7 million people in the United States alone. In those over the age of 65, it is also the leading cause of hospitalization. Patients with heart failure can benefit from remote monitoring to minimize unnecessary hospitalization, improve their quality of life, and improve their adherence.